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Abstract
Background: Prevention of disability (POD) is one of the key objectives of leprosy programmes. Recently, coverage and
access have been identified as the priority issues in POD. Assessing the cost-effectiveness of POD interventions is highly
relevant to understanding the barriers and opportunities to achieving universal coverage and access with limited resources.
The purpose of this study was to systematically review the quality of existing cost-effectiveness evidence and discuss
implications for future research and strategies to prevent disability in leprosy and other disabling conditions.
Methodology/Principal Findings: We searched electronic databases (NHS EED, MEDLINE, EMBASE, and LILACS) and
databases of ongoing trials (www.controlled-trials.com/mrct/, www.who.int/trialsearch). We checked reference lists and
contacted experts for further relevant studies. We included studies that reported both cost and effectiveness outcomes of
two or more alternative interventions to prevent disability in leprosy. We assessed the quality of the identified studies using
a standard checklist for critical appraisal of economic evaluations of health care programmes. We found 66 citations to
potentially relevant studies and three met our criteria. Two were randomised controlled trials (footwear, management of
neuritis) and one was a generic model-based study (cost per DALY). Generally, the studies were small in size, reported
inadequately all relevant costs, uncertainties in estimates, and issues of concern and were based on limited data sources. No
cost-effectiveness data on self-care, which is a key strategy in POD, was found.
Conclusion/Significance: Evidence for cost-effectiveness of POD interventions for leprosy is scarce. High quality research is
needed to identify POD interventions that offer value for money where resources are very scarce, and to develop strategies
aimed at available, affordable and sustainable quality POD services for leprosy. The findings are relevant for other
chronically disabling conditions, such as lymphatic filariasis, Buruli ulcer and diabetes in developing countries.
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Introduction
Leprosy is a leading cause of permanent disability among
communicable diseases. An estimated three million people live
with disability due to leprosy [1] and it is expected that up to one
million people will continue to suffer from disability in the next
decades [2]. The International Classification of Functioning,
Disability and Health (ICF) defines disability as ‘an umbrella term
for impairments, activity limitations and participation restrictions’
[3]. This definition goes beyond the concept of considering
disability in medical terms only, and recognises the social context
of disability. More than most other diseases, leprosy has a very
negative image. People with visible disability fear stigmatization
and discrimination, and experience serious psychosocial and
economic problems [4–6].
One of the main components of leprosy programmes and
research has been prevention of disability (POD). Interventions
include: early detection and treatment of reactions and nerve
damage, self-care interventions, health education, footwear
programmes, and reconstructive surgery. More recently, the need
for clear and sound guidance for leprosy control activities resulted
in the organization of a technical forum by the International
Leprosy Association (ILA). Their report, published in 2002,
reviewed the existing literature for the effectiveness of important
issues related to leprosy control, but did not address cost-
effectiveness [7]. In 2006, a Consensus Development Conference
on prevention of disability in chronically disabling conditions, such
as leprosy, lymphatic filariasis, Buruli ulcer and diabetes was held.
The main research theme of the conference was how to achieve
universal coverage of essential POD interventions. One of the
conclusions was that priority should be given to research that
addresses issues of coverage and access [8].
In developing or low-income countries, cost-effective interven-
tions often do not reach many of those who need them most.
Achieving universal coverage usually means ‘going to scale’,
defined as ‘a policy that builds on one or more interventions with
known effectiveness and combines them into a programme
delivery strategy designed to reach high, sustained, and equitable
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coverage, at adequate levels of quality, in all who need the
interventions’. It assumes that the chosen interventions for scaling
up are known to be feasible, affordable, and effective for
implementation in the specific setting [9].
Evidence for the effectiveness of POD interventions in leprosy
is limited. Recently, two systematic reviews have been published.
One review assessed the effects of corticosteroids for treating
nerve damage in leprosy [10] but did not find evidence from
randomised controlled trials for a significant long-term effect of
steroid therapy in improving either mild sensory nerve function
impairment [11] or longstanding nerve function impairment
[12].
The second review assessing the effects of interventions for skin
damage in leprosy [13] found weak evidence favouring topical
ketanserin over clioquinol cream or zinc paste [14] and topical
phenytoin over saline dressing [15,16] in ulcer healing. No
evidence from randomised controlled trials for the effectiveness of
self-care or educational interventions was found.
Cost-effectiveness data are even more limited, though the
importance of cost-effectiveness analysis has been recognised. The
ILA technical forum included a research question about which
methods are most cost-effective, but did not answer this question
in their report [7]. The consensus statement on POD mentioned
that it would be more cost-effective to combine POD strategies
and interventions for several related chronically disabling
conditions in leprosy-endemic countries, and recommended
further research on cost-effective methods to promote self-care
and the use of appropriate footwear [8].
We assessed the existing literature on cost-effectiveness of
POD interventions in leprosy as it was not clear which
interventions were most cost-effective, using a standard checklist
for economic evaluations and discussed the findings in the light
of availability, affordability, and sustainability of POD interven-
tions for leprosy and other chronically disabling conditions in
developing countries.
Methods
Searching
In November 2008, a systematic search was done. We searched
the NHS EED database (from 1994) using the search term:
leprosy. We searched MEDLINE (from 1966), EMBASE (from
1980), and LILACS (from 1982), using the strategy in table 1. We
searched databases of ongoing trials (www.controlled-trials.com/
mrct/, www.who.int/trialsearch), we checked reference lists for
any additional relevant studies, and we contacted experts in
leprosy for ongoing studies or unpublished data. There were no
language restrictions when we searched for publications.
Selection
We included studies that met the following criteria:
N assessing interventions to prevent disability in leprosy and
N comparing two or more competing alternatives and
N reporting both cost and effectiveness of the interventions
compared
There were no restrictions on the type of study design when we
searched for publications.
Validity assessment
We assessed the quality of the studies, using a check-list from
Drummond al. [17], consisting of ten essential questions, for
critically appraising studies of economic evaluation of health care
programmes (see table 2). With respect to question 10 (did the
presentation and discussion of study results include all issues of
concern to users), we focussed on availability, affordability, and
sustainability. Availability includes issues of coverage and access,
affordability means that each of the parties involved is able and
willing to pay for a given health care programme or intervention,
and sustainability refers to long-term strategies for sustaining
health care programmes.
Data abstraction and study characteristics
One author (NvV) extracted the relevant data (e.g. type of study
design, interventions, outcome measures) from the eligible studies
and a second author (PMN) checked the data. The authors
discussed discrepancies between themselves. Missing data were
obtained from study authors where possible. The authors were not
blinded to the names of study authors, journal or institutions.
Table 1. Search strategy for identifying economic evaluations
of interventions to prevent disability in leprosy.
# Term Field
1 economics MeSH Subheading
2 economic evaluation title or abstract
3 cost-benefit analysis title or abstract
4 cost-effectiveness analysis title or abstract
5 cost-effective title or abstract
6 cost-utility analysis title or abstract
7 cost title or abstract
8 costs title or abstract
9 or/1–8
10 leprosy title or abstract
11 hansen’s disease title or abstract
12 hansen disease title or abstract
13 or/10–12
14 disability title or abstract
15 disabled title or abstract
16 deformity title or abstract
17 deformed title or abstract
18 impairment title or abstract
19 impaired title or abstract
20 neuritis title or abstract
21 nerve damage title or abstract
22 nerve function impairment title or abstract
23 reaction title or abstract
24 reactions title or abstract
25 ulcer title or abstract
26 eye damage title or abstract
27 visual impairment title or abstract
28 blindness title or abstract
29 footwear title or abstract
30 self-care title or abstract
31 surgery title or abstract
32 or/14–31
33 9 and 13 and 32
doi:10.1371/journal.pone.0004548.t001
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Quantitative data synthesis
For studies with a similar type of POD intervention, we planned
to calculate standardised estimates of the cost per disability-
adjusted life-year (DALY). Where it was not possible to pool data,
we summarised the cost-effectiveness data for each study.
Results
Flowchart
The electronic searches found 62 citations to potentially relevant
studies. Two further potentially eligible studies were found from
reference lists of included studies and reviews. Correspondence with
experts in leprosy and searching of grey literature revealed another
two potentially relevant studies. We identified seven possible studies
of economic evaluation. The search of the ongoing trial registers did
not reveal any ongoing trials. We excluded four studies. One study
was a review paper describing only costs of different components of
a global leprosy elimination programme [18]. The second study
modelled the productivity gains if deformity would be eliminated
[19]. The third study assessed only the cost of offering disability care
either through community volunteers or leprosy workers at the
clinic [20]. The fourth study was an unpublished report describing
guidelines for doing a systematic cost analysis in leprosy control
programmes [21]. Figure 1 shows the selection process of the
studies.
Study characteristics
We included three studies. Two studies were small, single-centre
randomised controlled trials. One trial (Seboka 1996) assessed the
cost-effectiveness of canvas shoes compared to plastazote shoes in
terms of cost per ulcer healed or prevented [22]. The other trial
(Ravi 2004) compared the cost of ambulatory care to hospitalisa-
tion in the management of neuritis and used the number of days
needed to return to work as primary outcome of effectiveness [23].
The third study (Remme 2006) reviewed the effectiveness of
interventions and calculated cost of existing interventions per
DALY averted [24]. It was published in the second edition of the
World Bank publication ‘Disease Control Priorities in Developing
Countries’ [25]. Table 3 summarises the general characteristics of
the three studies.
Validity assessment
For a critical appraisal of the studies, we answered all ten questions
of the standard checklist [17] for each of the studies identified. The
results of the critical assessment are summarised in table 4.
1. Was a well-defined question posed in answerable
form?. The three studies did not state explicitly the viewpoint
for the analysis (e.g. a specific provider or providing institution, the
patient or groups of patients, a third-party payer, or society).
Seboka 1996 implicitly referred to third-party payers (donors) with
respect to long-term costs. Ravi 2004 estimated costs incurred by
the health sector and the patient, and indirect costs due to lost
working days, implying a societal perspective for the analysis.
Remme 2006 included only direct costs to the health system of
delivering interventions.
Table 2. Check-list for assessing economic evaluations.
1 Was a well-defined question posed in answerable form?
2 Was a comprehensive description of the competing alternatives given?
3 Was the effectiveness of the programmes or services established?
4 Were all the important and relevant costs and consequences for each
alternative identified?
5 Were costs and consequences measured accurately in appropriate physical
units?
6 Were costs and consequences valued credibly?
7 Were costs and consequences adjusted for differential timing?
8 Was an incremental analysis of costs and consequences of alternatives
performed?
9 Was allowance made for uncertainty in the estimates of costs and
consequences?
10 Did the presentation and discussion of study results include all issues of
concern to users?
From: Drummond al. 2005 (17).
doi:10.1371/journal.pone.0004548.t002
Figure 1. Flowchart of selection process.
doi:10.1371/journal.pone.0004548.g001
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2. Was a comprehensive description of the competing
alternatives given?. Seboka 1996 compared two types of
protective footwear, canvas shoes and plastazote or moulded
shoes. Ravi 2004 assessed neuritis management through either
ambulatory care or hospitalisation. Patients in the in-patient group
were admitted for two weeks and were monitored in the ward for
complications of steroid therapy. Patients receiving ambulatory
care were educated regarding the complications of steroids and
were advised rest at home for 2 weeks. Remme 2006 reviewed
several existing POD interventions, compared to doing nothing.
3. Was the effectiveness of the programmes or services
established?. Evidence of effectiveness of footwear and neuritis
management came from the trials itself (Seboka 1996 and Ravi
2004 respectively). Remme 2006 reviewed the literature for the
effectiveness of POD interventions. Early case detection and
treatment were considered as the most effective interventions to
prevent disability in leprosy, and self-care as the main strategy to
prevent worsening of impairments.
4. Were all the important and relevant costs and
consequences for each alternative identified?. Seboka
1996 included only the wholesale price for which the canvas
shoes were purchased. Plastazote shoes were provided free-of-
charge for the purpose of this study. The cost of organizing and
operating the footwear service or the cost to the patient and family
for follow-up visits was not measured. Ravi 2004 collected data on
different cost categories, covering direct medical costs (e.g.
examinations, medication, in-patient care), direct non-medical
costs (e.g. transport and food of visitors and patients) and indirect
costs (e.g. working days and wages lost), but it was unclear as to
whether shared costs were taken into account. Remme 2006
estimated only the direct health care cost of delivering
interventions.
Seboka 1996 used programme specific outcome measures of
effectiveness (change in ulcer size, the acceptability, usefulness and
durability of the footwear), but no generic quality of life outcome.
The occurrence of adverse effects was not explicitly addressed, but
the study did report that at least one out of five subjects in the
plastazote group, who were initially ulcer-free, developed ulcers
due to ill-fitting shoes. The primary outcome in Ravi 2004 was the
number of days needed to return to work and this was considered
a surrogate marker for effectiveness of treatment and well-being of
the patient. Secondary outcomes were: mean cost per patient,
improvement in nerve function scores and quality of life scores.
None of the patients reported any significant adverse effects of
steroid therapy. Remme 2006 used a generic outcome measure,
the disability-adjusted life years (DALYs) and did not report on
adverse effects.
5. Were costs and consequences measured accurately in
appropriate physical units?. The costs in Seboka 1996 were
straightforward, but inaccurate; the wholesale price or estimated
cost of a pair of shoes. Ravi 2004 calculated costs by multiplying the
quantities of the resources used and the unit cost of each resource
Table 3. General characteristics of included studies.
Study ID Seboka 1996 Ravi 2004 Remme 2006
Design Randomised controlled trial Randomised controlled trial Model-based study
Randomisation procedure Randomisation by day of attendance to clinic Randomisation by computerized random
numbers table
Not applicable
Setting Foot-care clinic near Sheshemane, Ethiopia Skin and leprosy department of tertiary
level hospital in Tamilnadu, India
Not applicable
Time of study November 1994 to November 1995 October 1999 to March 2001 Not applicable
Number of patients 70 26 Not applicable
Inclusion Leprosy patients with deformed and
anaesthetic feet
Leprosy patients with neuritis ,6 month
duration due to type 1 or type 2 reaction
Not applicable
Male/female 28/40 (2 unknown) 23/3 Not applicable
Mean age (range) Not described (unclear) 31 (15–49) (exp)1; 41 (19–60) (cont)2 Not applicable
Lost to follow-up 2 (cont)2 4 (2 exp, 2 cont)1 2 Not applicable
Interventions Experimental group (n = 40): canvas shoes Experimental group (n = 13): ambulatory
care: education and steroid therapy
(mean duration 4.3 months)
Treatment for reactions and ulcers,
footwear and self-care education,
reconstructive surgery
Control group (n = 30): plastazote shoes Control group (n = 13): hospitalisation
for 2 weeks plus steroid therapy (mean
duration 4.5 months)
Comparing total cost and benefits of
existing interventions, starting from
zero
Outcomes Healing of existing ulcers Number of days needed to return to work
after stipulated period of admission or rest
(2 weeks)
Cost per DALY averted
Prevention of ulceration Mean cost per patient Average cost of POD per new leprosy
case with disability
Acceptability of shoes Improvement in quality of life score
Durability of shoes Improvement in sensory and motor score
Cost-effectiveness of shoes
Timing of outcome
assessment
One year after start from study At the end of steroid therapy Not applicable
1exp: experimental group.
2cont: control group.
doi:10.1371/journal.pone.0004548.t003
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(e.g. cost of each examination, bed and nursing cost, transportation
cost). Remme 2006 measured cost as cost of an intervention per
patient. Costs were estimated from limited published cost data,
programme expenditure data, and expert opinion.
Seboka 1996 measured the primary outcome in natural units;
the number of ulcers healed or prevented. It was unclear what
scale or score was used to measure acceptability and usefulness of
the footwear. Ravi 2004 measured the primary outcome, the
number of days needed to return to work, from the stipulated
period of rest or admission. Improvement in nerve function was
measured as a mean score using graded nylon filaments (score per
nerve) and the Medical Research Council (MRC) scale (0–5 score
per nerve). Quality of life was measured as a mean score using a
questionnaire (20 questions, maximum score of 106) derived from
the WHO QOL Global pool of questions. Remme 2006 measured
the outcome in DALYs.
6. Were costs and consequences valued credibly?. Seboka
1996 reported the prevailing wholesale price of a pair of canvas
shoes in US dollars. Ravi 2004 reported costs in local currency
(Indian rupees) based on prevailing prices. Remme 2006 converted
cost estimates to US dollars 2000.
Seboka 1996 and Ravi 2004 measured the primary outcome in
natural units, which does not require valuation of benefits in
money terms. Remme 2006 valued outcomes in DALYs. The
disability weights used to value the duration and severity of a
particular disease or condition have been criticised, because these
were established by expert opinion and consensus [26]. For
leprosy, a disability weight of 0.152 was given to disabling leprosy
and a weight of 0.000 to a leprosy case without disability [27].
These weights are likely to be underestimated, since they will not
adequately capture all the disability resulting from leprosy, such as
the major psychosocial impact of leprosy on the lives of leprosy
patients, regardless of having disability or not [24].
7. Were costs and consequences adjusted for differential
timing?. Because Seboka 1996 was a one-year trial and all the
costs and consequences occurred within a one-year period, no
discounting was needed. The trial of Ravi 2004 had a duration of
1.5 years. The study did not report on discounting. In Remme
2006 discounting of costs was done using a 3% rate. The DALY
incorporates a constant annual discount rate of 3% for outcomes
[28].
8. Was an incremental analysis of costs and consequences
of alternatives performed?. Seboka 1996 and Ravi 2004 did
not perform an incremental analysis. Although the canvas shoes
and ambulatory care intervention had lower costs and higher
effectiveness compared to the plastazote shoes and hospitalisation
intervention respectively, no information on a statistically
significant difference between the two competing alternatives
was given. Remme 2006 calculated the average cost-effectiveness
of existing interventions.
9. Was allowance made for uncertainty in the estimates of
costs and consequences?. None of the studies performed a
sensitivity analysis.
10. Did the presentation and discussion of study results
include all issues of concern to users?. Availability: none of
the studies discussed the issue of coverage and access.
Affordability: none of the studies discussed whether all parties
involved would be able and willing to pay for POD programmes.
Table 4. Quality of included studies.
Study ID
Criteria Seboka 1996 Ravi 2004 Remme 2006
1) Well-defined question stated? noa noa noa
2) Description of alternatives given? yes yes yes
3) Evidence of effectiveness established? yes yes yes
4) Relevant costs and outcomes identified? nob not surec nod
5a) Costs measured accurately? noe yes nof
5b) Outcomes measured accurately? no yes yes
6a) Costs valued credibly? yes yes yes
6b) Outcomes valued credibly? not applicableg not applicableg not sureh
7a) Costs discounted? not applicablei not surej yes
7b) Outcomes discounted? not applicablei not surej yes
8) Incremental analysis performed? no no no
9) Sensitivity analysis performed? no no no
10a) Issue of availability addressed? no no no
10b) Issue of affordability addressed? no no no
10c) Issue of sustainability addressed? yes no no
ano viewpoint for the analysis stated.
bonly cost of shoes included.
cnot sure whether shared costs were taken into account.
donly direct health care cost included.
ewholesale price or estimated cost of pair of shoes.
festimated costs based on limited published data and expert opinion.
goutcomes in natural units.
hdisability weights of DALY based on consensus of experts, but not on patient’s values or preferences.
iall costs and consequences occurred within one year.
jnot sure whether discounting was done.
doi:10.1371/journal.pone.0004548.t004
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Sustainability: Seboka 1996 mentioned that the cost of
providing footwear to patients for many years may be costly and
will require long-term commitment from donors. The other studies
did not discuss issues of sustainability.
Quantitative data synthesis
We summarised the cost-effectiveness data for each study,
because it was not possible to pool the data for calculating
standardised estimates of the cost per disability-adjusted life-year
(DALY). Seboka 1996 calculated the cost-effectiveness of canvas
shoes compared to plastazote shoes to prevent and heal ulcers in
leprosy patients with deformed and anaesthetic feet. The average
cost per ulcer healed or prevented over a one-year period was
$24.4 and $44.7 respectively. Additional information about the
results of the plastazote group was obtained from one of the
authors. The average cost per ulcer healed or prevented over a
one-year period was at minimum $160 and $373 respectively.
Ravi 2004 calculated costs and effectiveness of ambulatory care
compared to hospitalisation in the management of neuritis due to
reactions in leprosy patients. The total mean cost per patient was
approximately 7,234 rupees for ambulatory care versus 25,740
rupees for in-patient care. On average, patients receiving
ambulatory care returned to work after 19.5 days, while
hospitalized patients needed 66.8 days to return to work.
Additionally, the study measured quality of life, but results for
only 17 out of 26 patients were available. QOL scores improved in
both groups, but the study did not find a significant mean
difference in the pre- and post-treatment QOL scores between the
two groups.
Remme 2006 estimated the average cost of POD for each new
case of leprosy detected with disability at $44.10. The cost per
DALY was calculated assuming a 25% self-cure rate, an average
age of onset of 27, a disability weighting of 0.152, a life expectancy
at age 25–29 of 44.75 (India data), and a 90% success rate. The
cost per DALY for patients needing treatment for reactions and
ulcers was estimated at $7, for those needing footwear and self-
care education at $75, for those needing reconstructive surgery at
$110.
Discussion
Summary of main findings
Evidence for cost-effectiveness of POD interventions for leprosy
is scarce. We found three studies; two were small, single-centre
randomised controlled trials and one was a model-based review
study. One trial found that canvas shoes were more cost-effective
than plastazote shoes in healing and preventing ulcers and the
other trial showed that ambulatory care was more cost-effective
(lower cost and earlier return to work) compared to hospitalisation
in the management of neuritis. The model-based study estimated
the cost of POD interventions per DALY averted between $7 and
$110. None of the studies met all the quality criteria for economic
evaluations. The cost perspective of the analysis, relevant and
accurate costs, analysis of uncertainty in estimates, and issues of
availability, affordability and sustainability were inadequately
reported or addressed in the studies.
Generalizability
Generalizability of the findings is limited. The two trials [22,23]
were conducted in a single centre and used prevailing or local
prices to calculate costs. The economic evaluation was carried out
alongside a randomised controlled trial and it has been argued that
economic outcomes from such trials may differ significantly from
usual practice or care [17]. The model-based study [24] stated that
costs were likely to differ country by country and that the cost
estimates should only be considered indicative, as they were based
on limited published data and expert opinion. The cost of
prevention of disability per new leprosy case with disability was
expected to be higher than the estimate due to a backlog of old
leprosy cases with disability, and this cost will be influenced by the
numbers of multibacillary leprosy patients and the levels of
disability in different settings and countries. The cost-effectiveness
outcomes were also likely to vary, because these were based on
limited effectiveness data, and the application of a disability weight
of 0.152 to all patients may overestimate the benefits of
interventions.
Issues of concern
One of the criteria for critically assessing economic evaluations
was whether studies discussed all issues of concern. We focussed on
issues of availability, affordability and sustainability, since these are
current challenges in resource-poor countries and for neglected
tropical diseases. Few studies have addressed one of these issues.
Whilst self-care appears to be an effective, affordable and
sustainable intervention to prevent disability in leprosy or
lymphatic filariasis, when initially taught and supervised by
general health staff [29–31], we are not aware of evidence that
has documented the cost-effectiveness of self-care strategies. The
ILA technical forum report highlighted the need for sustainable
leprosy services through integrated general health services and
provided basic requirements for this process, such as involvement,
commitment and collaboration of the different stakeholders and
health staff, strengthening of health systems, and careful planning
[7]. Also, patients should be adequately informed about the
availability of existing POD services [32].
Achieving universal coverage would require cost-effective POD
interventions that can be delivered at adequate quality levels to all
who need them and for as long as needed. Strategies for going to
scale need to consider the context or setting of implementation
(e.g. skilled staff and resources available, burden of disease,
benefits to others than target group), the balance between quality
and coverage levels, the choice of the health delivery system (e.g.
general health services, disease-specific programmes, community-
based health workers, or mix of alternatives), costs involved (e.g.
strengthening health systems), and longer-term planning [9].
Strengths of the study
This is the first study that critically and systematically reviewed
the existing literature on cost-effectiveness of interventions to
prevent disability in leprosy. The search process was elaborate and
to our knowledge no other studies were available for the review.
We used a standard checklist to appraise the quality of economic
evaluations of health care programmes and health interventions.
Limitations of the study
It is possible that not all of the relevant studies have been
included in this review, and that we failed to find some
unpublished ones. We contacted several experts in leprosy, but
this did not reveal any unpublished or ongoing studies. We were
not able to compare the cost-effectiveness of similar interventions
or calculate standardised outcome estimates, due to lack of data on
costs and effectiveness outcomes. Recently, two questionnaires on
aspects of quality of life were developed and validated for
chronically disabling conditions, such as leprosy, polio, spinal
cord injuries and diabetes. One questionnaire (SALSA) measures
limitations in daily activities [33], and the other one (Participation
Scale) assesses perceived restrictions in social participation [34].
These questionnaires may be useful in assessing and comparing
Costs of POD in Leprosy
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the effects of interventions and programmes for chronic and
disabling conditions on patient-perceived changes in quality of life.
In conclusion, cost-effectiveness analysis should play an
important role in the informed debate about issues of availability,
affordability and sustainability of health care programmes or
health interventions for chronically disabling diseases, such as
leprosy, lymphatic filariasis, Buruli ulcer and diabetes, in resource-
poor countries. It is recommended that future economic
evaluation studies better define the cost perspective, the relevant
alternatives, costs and outcomes of POD interventions, including
adverse effects, and potentially uncertain variables, and to address
issues of availability, affordability and sustainability. Future studies
are needed to establish the cost-effectiveness of POD interventions
and these should adhere to standard guidelines for economic
evaluations.
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